Literatur
- 1 Fülgraff G, Palm D. Pharmakotherapie - klinische Pharmakologie. Stuttgart: Gustav
Fischer Verlag 1995
- 2
Greening A P, Ind P W, Northfield M, Shaw G.
Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms
on existing inhaled corticosteroid.
Lancet.
1994;
344
219-224
- 3
Woolcock A, Lundback B, Ringdal N, Jacques L A.
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose
of inhaled steroids.
Am J Respir Crit Care Med.
1996;
153
1481-1488
- 4
Pauwels R A, Löfdahl C G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J, Ullmann A.
Effect of inhaled formoterol and budesonide on exacerbations of asthma.
N Engl J Med.
1997;
337
1405-1411
- 5
Hancox R J, Cowan J O, Flannery E M, Herbison G P, McLachlan C R, Wong C S, Taylor D R.
Randomised trial of an inhaled β2 agonist, inhaled corticosteroid and their combination in the treatment of asthma.
Thorax.
1999;
54
482-487
- 6
Wiewroth R, Dauletbaev N, Buhl R.
Wirksamkeit und Verträglichkeit einer Kombination von Fluticason und Salmeterol bei
Patienten mit obstruktiver Atemwegserkrankung.
Pneumologie.
1997;
51
14-20
- 7
Chung K F.
The complementary role of glucocorticosteroids and long-acting β-adrenergic agonists.
Allergy.
1998;
53
7-13
- 8
Taylor D R, Hancox R J.
Interactions between corticosteroids and beta agonists.
Thorax.
2000;
55
595-602
- 9
Eickelberg O, Roth M, Lörx R, Bruce V, Rudiger J, Johnson M, Block L H.
Ligand-independent activation of the gluccocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth
muscle cells.
J Biol Chem.
1999;
274
1005-1010
- 10
Andersson F, Stahl E, Barnes P J, Löfdahl C G, O'Byrne P M, Pauwels R A, Postma D S,
Tattersfield A E, Ullmann A.
Adding formoterol to budesonide in moderate asthmatics is cost-effective - results
from the “FACET” study.
Am J Respir Crit Care Med.
2000;
161
A787
- 11
Bisgaard H.
Long-acting β2-agonists in management of childhood asthma: a critical review of the literature.
Pediatr Pulmonol.
2000;
29
221-234
- 12
Kips J C, O'Connor B J, Inman M D, Svensson K, Pauwels R A, O'Byrne P M.
A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol
versus high-dose budesonide in asthma.
Am J Respir Crit Care Med.
2000;
161
996-1001
- 13
Chapman K R, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M.
Salmeterol and fluticasone propionated (50/250 μg) administered via combination diskus
inhaler: as effective as when given via separate diskus inhalers.
Can Respir J.
1999;
6
45-51
- 14
Bateman E D, Britton M, Carrillo T, Almeida J, Wixon C.
Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment
for asthma.
Clin Drug Invest.
1998;
16
193-201
- 15
Aubier M, Pieters W R, Schlosser N J, Steinmetz K O.
Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler
(Seretide) is effective and safe in the treatment of steroid-dependent asthma.
Respir Med.
1999;
93
876-884
- 16
Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A,
Shah T.
Salmeterol and fluticasone propionate combined in a new powder inhalation device for
the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
J Allergy Clin Immunol.
2000;
105
1108-1116
- 17
Jenkins C, Woolcock A J, Saarelainen P, Lundback B, James M H.
Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more
effective than budesonide 800 μg twice daily in treating moderate to severe asthma.
Respir Med.
2000;
94
715-723
- 18
Buhl R, Kardos P, Magnussen H, Matthys H, Sauer R, Schauer P, Vogelmeier C, Wettengel R,
Worth H, Menz G.
Feste Kombination inhalierbarer Kortikoide und langwirkender β2-Sympathomimetika zur Langzeittherapie des Asthma bronchiale.
Pneumologie.
1999;
53
210-212
- 19 Zetterström O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S. Budesonide and
formoterol in a single inhaler, Symbicort®, improves asthma control in adults: a randomised
controlled study. Eur Respir J im Druck 2001
- 20
Zetterström O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S, Peterson S.
The new single inhaler product containing both budesonide/formoterol improves asthma
control in adults.
Eur Respir J.
2000;
16
455s
- 21
Zetterström O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S, Ekström T.
Efficacy and safety of a new single inhaler product, containing both budesonide and
formoterol in adult asthma.
Eur Respir J.
2000;
16
455s
- 22
Vermeulen J H, Simon G, Tal A, Vit P, Cobos N, Everara M L, De Boeck C, Peterson S.
Improved lung function and rapid control achieved with the new single inhaler product
containing both budesonide and formoterol in asthmatic children aged 4 - 17 years.
Eur Respir J.
2000;
16
384s
- 23
Tal A, Simon G, Vermeulen J H, Vit P, Cobos N, Everard M L, De Boeck C, Jerre F.
The benefit of the new single inhaler product containing both budesonide and formoterol
in asthmatic children.
Eur Respir J.
2000;
16
384s
- 24
Coutts J AP, Gibson N A, Paton J Y.
Measuring compliance with inhaled medication in asthma.
Arch Dis Child.
1991;
67
332-333
- 25
Balsbaugh T A, Chambers C V, Diamond J J.
Asthma controller medications: what do patients want.
K Asthma.
1999;
36
591-596
- 26 Kardos P, Brüggenjürgen B, Martin A, Meyer-Sabellek W, Richter K, Vogelmeier C,
Willich S N, Buhl R. Die Behandlung des Asthma bronchiale nach einem bedarfsorientierten
Behandlungsplan. Eingereicht 2001
- 27
Cochrane G M.
Compliance and outcomes in patients with asthma.
Drugs.
1996;
52
12-19
- 28
Cramer J A, Mattson R H, Prevey M C, Scheyer R D, Ovellette V L.
How often is medication taken as prescribed.
JAMA.
1989;
261
3273-3277
- 29
Dompeling E, van Grunsven P M, van Schayck C P, Folgernig H, Molema J, van Weel C.
Treatment with inhaled steroids in asthma and chronic bronchitis: long term compliance
and inhaler technique.
Fam Pract.
1992;
9
161-166
- 30
Gerrits C MJM, Herings R MC, Lammers J WJ, Leufkens H GM.
Too low usage of inhaled steroids among patients with long-acting β2-agonists.
Eur Respir J.
1998;
12
156s-157s
- 31
Horn C R, Essex E, Hill P, Cochrane G M.
Does urinary salbutamol reflect compliance with the aerosol regimen in patients with
asthma.
Resp Med.
1989;
83
15-18
- 32
Bosley C M, Parry O T, Cochrane G M.
Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids
improve compliance.
Eur Respir J.
1994;
7
504-509
- 33
Kelloway J S, Wyatt R A, Adlis S A.
Comparison of patients' compliance with prescribed oral and inhaled asthma medications.
Arch Int Med.
1994;
154
1349-1352
- 34
Barnes P J, Woolcock A J.
Difficult asthma.
Eur Respir J.
1998;
12
1209-1218
- 35
Ankerst J, Persson G, Weibull E.
A high dose of budesonid/formoterol in a single inhaler was well tolerated by asthmatic
patients.
Eur Respir J.
2000;
16
33s
- 36
British Thoracic Society .
The british guidelines on asthma management. Asthma in adults and schoolchildren.
Thorax.
1995;
52
S2-S8
- 37
Wettengel R, Berdel D, Hofmann D, Krause J, Kroegel C, Kroidl R F, Leupold W, Lindemann H,
Magnussen H, Meister A, Morr H, Nolte D, Rabe K, Reinhardt D, Sauer R, Schultze-Werninghaus G,
Ukena D, Worth H.
Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga
in der Deutschen Gesellschaft für Pneumologie.
Med Klinik.
1998;
93
39-50
- 38 National Institutes of Health .Global strategy for asthma management and prevention
NHLBI/WHO Workshop report. U. S. Department of Health and Human Services, Bethesda
1993
- 39 National Institutes of Health .International consensus report on diagnosis and
management of asthma. U. S. Department of Health and Human Services, Bethesda 1992
- 40
Wallin A, Sandstrom T, Rosenhall L, Melander B.
Time course and duration of bronchodilatation with formoterol dry powder in patients
with stable asthma.
Thorax.
1993;
48
611-614
- 41
Tattersfield A E, Löfdahl C G, Postma D S, Ekström T, Eivindson A, Schreurs A, Rasidakis A,
Karlsson K, Larsson P.
On demand treatment: comparision of formoterol and terbutaline in moderate asthma.
Am J Respir Crit Care Med.
1999;
159
A636
- 42
Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J.
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action,
duration of effect and potency.
Eur Respir J.
1997;
10
2484-2489
- 43
Dahl R.
Comparative studies of inhaled salmeterol with other bronchodilators.
Eur Respir J.
1995;
5
138-141
- 44
Gillissen A, Buhl R, Kardos P, Magnussen H, Matthys H, Rabe K F, Rothe T, Russi E W,
Schuaer J, Schmitz M, Vogelmeier C, Wettengel R, Worth H, Menz G.
Inhalierbare Kortikosteroide in der Langzeittherapie der COPD. Stellungnahme eines
Expertengremiums.
Pneumologie.
2000;
54
256-262
Prof. Dr A Gillissen
Robert-Koch-Klinik
Nikolai-Rumjanzew-Str. 100
04207 Leipzig
eMail: E-mail: adrian.gillissen@sanktgeorg.de
